D'Albert Hofmann au 4-Pro-MET : histoire des tryptamines

L'histoire de la recherche sur les tryptamines commence avec une bicyclette. Le 19 avril 1943, Albert Hofmann pédalait sous l'influence du LSD – un ergoline, pas une tryptamine au sens strict, mais l'étincelle de la recherche psychédélique – à travers Bâle. Ce qui s'ensuivit : 80 ans de recherche, d'interdictions, de renaissance et le développement de substances comme le 4-Pro-MET. Des laboratoires Sandoz de Hofmann aux tryptamines synthétiques du XXI e siècle.

Albert Hofmann synthesized LSD (lysergic acid diethylamide) at Sandoz Laboratories in Basel, Switzerland in 1938. Five years later came the accident that changed everything. On April 19, 1943 – now commemorated as "Bicycle Day" – Hofmann absorbed a small quantity through his skin and experienced altered perception during his ride home. LSD is a lysergamide, not a tryptamine. But Hofmann's discovery cracked open the door to systematic psychedelic research.

Tryptamines came next. In 1958, Hofmann synthesized psilocybin and psilocin from Psilocybe mexicana mushrooms. By 1960, he'd determined their chemical structures and developed synthetic production methods. These discoveries put 4-substituted tryptamines on the map alongside lysergamides and phenethylamines. And the research boom that followed was staggering: between 1950 and 1970, approximately 1,000 scientific papers were published on psychedelic tryptamines, and an estimated 40,000 patients received psilocybin or LSD in therapeutic settings.

Alexander « Sasha » Shulgin (1925–2014) a porté le travail de Hofmann à un niveau systématique. Dans son laboratoire privé en Californie, il a synthétisé et testé des centaines de phénéthylamines et de tryptamines – dont le 4-HO-MET, le métabolite actif du 4-Pro-MET.

TiHKAL (1997) a documenté 55 tryptamines avec des protocoles de synthèse et d'auto-expérimentation. Sur le 4-HO-MET (entrée #21), Shulgin écrivait : « Qualitatively a lot like psilocin. I started within the first half-hour, and at the max, I felt the same alteration of color and form » – dose 10–20 mg, durée 4–6 heures.

Son approche était simple et ingénieuse : changer une variable (par exemple la N-substitution), maintenir le reste constant, documenter l'effet. Cela a posé les bases de la recherche moderne des relations structure-activité (SAR) pour les tryptamines. Le 4-Pro-MET s'inscrit dans cette tradition : il fait varier l'ester en position 4 (propionyloxy au lieu d'acétyloxy) avec le même motif N-méthyl-N-éthyl.

The modern psychedelic renaissance began in 2006 when Roland Griffiths' team at Johns Hopkins published their landmark psilocybin study – demonstrating its ability to occasion mystical-type experiences with lasting positive effects. Clinical trials followed fast: by 2026, over 15 Phase II/III trials are active or completed for psilocybin alone, targeting treatment-resistant depression, PTSD, alcohol use disorder, and end-of-life anxiety.

The research chemical market expanded in parallel. 4-HO-MET appeared as a designer substance around 2008, 4-AcO-MET and 4-AcO-DMT gained popularity through the mid-2010s, and 4-Pro-MET emerged in August/September 2025 as the latest iteration of the 4-substituted tryptamine prodrug strategy. Each compound applies Shulgin's foundational chemistry to generate legal variants with predictable pharmacological profiles.